Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

149.76 -1.64 (-1.08%)
Streaming Delayed Price Updated: 1:24 PM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
71 72 Next >
News headline image
3 Stocks With Mouthwatering Dividends You Can Buy Right Now ↗
These stocks offer great dividends and more. 
Via The Motley Fool
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA
From Gilead Sciences, Inc.
Via Business Wire
News headline image
$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today ↗
 
Via Benzinga
News headline image
Should You Buy the 3 Highest-Yielding Dividend Stocks in the Nasdaq-100? ↗
If you're looking for big income from blue-chip companies, these picks are for you. 
Via The Motley Fool
News headline image
The Dividend Dynamos: 7 Stocks That Will Energize Your Income Stream ↗
Looking for some safe higher-yielding dividend stocks today? These are seven of the best options in this volatile market. 
Via InvestorPlace
News headline image
7 Dividend Stocks to Invest In for a Lifetime of Income ↗
Discover top dividend stocks to buy for 2024 to maximize profits and minimize risks in today’s investing environment. 
Via InvestorPlace
News headline image
Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis
From Gilead Sciences, Inc.
Via Business Wire
News headline image
National Institutes of Health Kickstarts Gilead Sponsored Trials For Twice-Yearly HIV Prevention Injection ↗
The US National Institutes of Health has launched two clinical trials to test a new long-acting form of HIV PrEP in cisgender women and people who inject drugs. These mid-stage studies will evaluate... 
Via Benzinga
News headline image
3 Dividend Stocks That Even Ken Griffin Is Buying ↗
Billionaire investor Ken Griffin is filling the portfolio of his Citadel Advisors hedge fund with dividend paying stocks. 
Via InvestorPlace
News headline image
Large Cap BIopharmaceuticals Overview ↗
As a defensive play healthcare is weighted at about 12% of the S&P 500. 
Via Talk Markets
Topics Stocks
News headline image
After Disappointing Bladder Cancer Data, Gilead Announces Encouraging Data From Gastric, Colorectal Cancer Studies ↗
Gilead Sciences and Arcus Biosciences report sustained efficacy and safety in the Phase 2 EDGE-Gastric study for upper GI cancers, showing improved progression-free survival and objective response... 
Via Benzinga
News headline image
Kite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead's Trodelvy Fails To Hit Primary Goal In Late-Stage Study With Most Common Type Of Bladder Cancer ↗
Gilead Sciences' announced topline results from the Phase 3 TROPiCS-04 study on Trodelvy for metastatic urothelial cancer. The study did not meet the primary endpoint of overall survival but showed... 
Via Benzinga
News headline image
EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Provides Update on Phase 3 TROPiCS-04 Study
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Is Nvidia Worth 35x Times Sales, History Says No ↗
You wouldn’t be able to tell just by looking at the S&P 500 daily change of +0.02%, but Tuesday was a pretty negative day, with the S&P 500 equal weight RSP ETF finishing down by almost 70 bps. 
Via Talk Markets
Topics ETFs Stocks
News headline image
2 Beaten-Down Dividend Stocks to Buy and Hold For 10 Years ↗
These companies have grown their dividends despite some troubles. 
Via The Motley Fool
News headline image
7 Biotech Stocks to Put on Your Breakthrough Radar ↗
Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance. 
Via InvestorPlace
News headline image
3 Biotech Stocks to Buy Now: May 2024 ↗
As the biotech industry continues to rise in market prominence, investors should start considering what the best biotech stocks to buy are. 
Via InvestorPlace
News headline image
Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Large Cap Biopharmaceuticals Performance ↗
The biotech sector remains a laggard YTD as can be seen by the IBB​​​​​​​. 
Via Talk Markets
News headline image
Gilead's Recently Acquired Liver Disease Candidate Shows Improvements In Disease Progression And Associated Itch ↗
Gilead Sciences reports interim results from the ASSURE study of seladelpar in primary biliary cholangitis, showing significant improvements in cholestasis markers and pruritus. 
Via Benzinga
News headline image
The P3 App: Empowering and Elevating Underprivileged Youth from Socioeconomically Disadvantaged Areas Through Innovative Mentorship
CHICAGO - May 18, 2024 - PRLog -- The Pulse of Perseverance alongside Gilead is proud to announce the launch of the P3 mobile app, a pioneering platform unveiled at our signature benefit event on May... 
Via PRLog
News headline image
Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch ↗
Penny stocks to buy understandably offers many enticing attributes, not least of which is the potential for tremendous returns. 
Via InvestorPlace
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
71 72 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.